HK inno.N and Boryung to carry out co-promotion and sales of K-CAB and Kanarb
December 20, 2023
HK inno.N and Boryung to carry out co-promotion and sales of K-CAB and Kanarb
HK inno.N and Boryung to carry out co-promotion and sales of GERD treatement, K-CAB and hypertension treatment Kanarb
HK inno.N to co-promote Boryung’s Kanarb, Dukaro, Dukarb and Dukarb
Boryung to co-promote HK inno.N’s K-CAB and K-CAB ODT
Both Companies to aim for market dominance and success through co-promotion scheme
Two of the largest Korean pharma companies, HK inno.N and Boryung are joining hands in the co-promotion and sales of blockbuster novel drugs in Korea. The co-promotion will specifically be targeting K-CAB, HK inno.N’s novel drug for GERD, and Kanarb, Boryung’s novel drug for hypertension. Marking the first case of collaboration in the two companies’ history, the co-promotion and sales scheme is expected to capitalize the two companies’ strengths to re-affirm the drugs’ dominant position in the Korean market for novel drugs.
HK inno.N and Boryung announced on December 20th HK inno.N’s novel, GERD treatment drug, K-CAB (API Tegoprazan) and, Boryung’s novel hypertension treatment drug, Kanarb (API Fimasartan) Vill be co-promoted and co-marketed during the agreed duration of the contract. K-CAB and Kanarb are both blockbuster drugs in Korea that in which they are significant in showing Korea’s ability to develop novel drugs, with annual prescriptions worth KRW 100 billion being issued.
The two companies will be joining hands in the co-promotion and sales of the drugs starting in January, 2024. The drugs to be co-promoted under the new agreement include all K-CAB products (i.e. K-CAB Tablet and K-CAB Orally Disintegrating Tablet) and the four Kanarb products. (i.e. Kanarb, Dukaro, Dukarb and Dukarb Plus).
HK inno.N, while asserting its dominance in the GERD treatment market with K-CAB, has simultaneously elevated their position in the chronic disease market with Boryung’s Kanarb added to their portfolio.
The co-promotion agreement between the two companies is a notable one and a first of its kind. Two companies that have successfully developed and commercialized a novel drug, coming together and joining forces to co-promote those successful novel drugs is expected to provide both companies with a competitive advantage and a growth momentum.
HK inno.N’s K-CAB, Korea’s 30th novel drug, is a GERD treatment drug that belongs to the P-CAB category. HK inno.N’s K-CAB has a onset time of 30 minutes, as well as proven efficacy and safety when administered over a long period of time. K-CAB 50mg was launched in 2019 as a tablet formulation and was shortly followed by a orally disintegrating formulation and a half dose tablet formulation
As of 2022, K-CAB has accumulated a total of KRW 132.1 billion in prescriptions (Source : UBIST, making it the no.1 GERD treatment in Korea
Boryung’s Kanarb is Korea’s 15th novel drug, the first hypertension novel drug to be developed and commercialized in Korea. It has been consistently bringing to market various combinations to cater to not only a wide range of hypertension patients but also those seeking to treat comorbidities. With a total of seven product types under the Kanarb umbrella, the brand reached KRW 150.3 billion worth in cumulative prescriptions in 2022 (Source : UBIST). Within the Kanarb product category, Tuvero and Akarb are co-promoted with Daewon Pharmaceutical.
HK inno.N’s CEO Dalwon Kwak commented, “With the experience in having successfully launched blockbuster drugs in the Korean market, the two companies will be able to generate further synergy through this co-promotion and re-affirm the leading status of their respective drugs in the market. The win-win partnership with Boryung will not stop here; We will continue to look for further opportunities for collaboration.”
Meanwhile, President of Boryung’s CEO Duhyeon Chang noted, “We hope that this latest collaboration in promoting the products of the two companies will go down as one of the best practices in the history of novel drug development in Korea. By combining the knowhow in successfully bringing novel drugs to market and promoting their unique values supported by clinical data, the two companies will be able to boost the prestige of leading novel drugs developed in the country and open up new opportunities for further growth.” [The end]
[For reference]
▶P-CAB: Potassium-Competitive Acid Blocker
▶ARB: Angiotensin II Receptor Blocker
▶K-CAB products included in the co-promotion initiative:
K-CAB Tablet (25mg, 50mg), K-CAB Orally Disintegrating Tablet (50mg)
▶Kanarb products included in the co-promotion initiative:
-Kanarb (Fimasartan, 30mg, 60mg, 120mg)
-Dukaro (Fimasartan/Amlodipine/Rosuvastatin, 30/5/5mg, 30/5/10mg, 60/5/5mg, 60/5/10mg)
-Dukarb (Fimasartan/Amlodipine, 30/5mg, 60/5mg, 30/10mg, 60/10mg)
-Dukarb Plus (Fimasartan/Amlodipine/Hydrochlorothiazide, 30/5/12.5mg, 60/5/12.5mg, 60/5/25mg, 60/10/12.5mg)